A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

NCT03565445 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

190

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: ASP1948
DRUG: nivolumab
DRUG: pembrolizumab

Sponsor

Astellas Pharma Global Development, Inc.

Collaborators

[object Object]